Shares of bluebird bio were down in trading after the U.S. Food and Drug Administration declined to review a Biologics License Application for the experimental CAR-T treatment idecabtagene vicleucel for multiple myeloma co-developed with Bristol Myers Squibb.

Geneius Biotechnology is developing T cells as a quasi-personalized, off-the-shelf, therapy and preventive measure against COVID-19.

Researchers with the Abramson Cancer Center of the University of Pennsylvania, led by Carl June, published results from the first U.S. Phase I trial of CRISPR-Cas9-edited T-cells in humans with advanced cancer.

The immuno-oncology therapy CAR-T utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.

Researchers from the Abramson Cancer Center of the University of Pennsylvania described a death receptor pathway in cancer cells that has a primary role in its response to CAR-T cells.

San Diego-based Sorrento Therapeutics rejected a non-binding acquisition proposal from a private equity firm, saying that the offer “significantly undervalues Sorrento and is not in the best interest of the company’s stockholders.”

BioNTech will acquire Neon Therapeutics Inc. in an all-stock transaction valued at approximately $67 million.

Bristol-Myers Squibb Co. anticipates receiving U.S. approvals for all three experimental drugs tied to a potentially higher payout for Celgene shareholders under terms of the U.S. biotech company’s acquisition, Bristol’s chief medical officer said.

A California jury awarded $752 million to Bristol-Myers Squibb over a patent infringement regarding the technology related to a novel cancer therapy.

Gilead subsidiary Kite submitted a Biologics License Application to the U.S. Food and Drug Administration for the investigational chimeric antigen receptor (CAR) T cell therapy KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.